AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3046300
Drug: Glucose loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose loading (100 g glucose) in non-pregnant women
Trial: 3046300
Drug: Glucose loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose loading (100 g glucose) in early-pregnant women
Trial: 3046300
Drug: Glucose loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose loading (100 g glucose) in late-pregnant women
Trial: 21566549
Drug: CST+OS (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST+OS (conventional standard therapy combined with oral supplementation) for 4 months
Trial: 21566549
Drug: CST (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST (conventional standard therapy alone)
Trial: 19943706
Drug: Sorafenib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib, a multi‐tyrosine kinase inhibitor, approved as first‐line therapy in HCC.
Trial: 15636308
Drug: S‐Amlodipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐Amlodipine 2.5 mg
Trial: 11376633
Drug: Cerivastatin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.4 mg once daily)
Trial: 2892544
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of famotidine
Trial: 2892544
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of famotidine
Trial: 30777900
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 8 mg/2 mL
Trial: 30777900
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 mL of saline)
Trial: 24093810
Drug: Stages of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stages of change (contemplation and preparation)
Trial: 18294484
Drug: Simvastatin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (n = 124; 160 mg total, 40 mg orally every 12 hours starting the evening before and ending the morning after the procedure)
Trial: 11190646
Drug: Open dorsoventral
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open dorsoventral interval therapy using the TAC
Trial: 9083323
Drug: Norgestimate-ethinyl estradiol
RxNorm normalized name: norgestimate-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate-ethinyl estradiol (active OC treatment)
Trial: 8471696
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg brofaromine twice a day
Trial: 8471696
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg phenelzine three times a day
Trial: 3534966
Drug: Postoperative total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative total pelvic irradiation plus misonidazole (MISO) (1 g/m2 orally 2 h before the first daily fraction)
Trial: 3534966
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (cystectomy alone)
Trial: 16335887
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day)
Trial: 16335887
Drug: Candesartan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (12 mg/day) - up-titrated monotherapy
Trial: 16335887
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release nifedipine plus candesartan combination therapy
Trial: 16335887
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with controlled release nifedipine and low-dose candesartan
Trial: 11910308
Drug: Losartan titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan titration to 100 mg
Trial: 11910308
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg addition
Trial: 4723266
Drug: Quinine dihydrochloride
RxNorm normalized name: quinine dihydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine dihydrochloride (490 mg base) via intravenous infusion every 8 hours for 3 days (1.47 gm base daily)
Trial: 4723266
Drug: Enteric‐coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric‐coated tablets of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Trial: 4723266
Drug: Gelatin capsules
RxNorm normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Trial: 23037875
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of surfactant (up to 5 doses) plus prolonged inhaled nitric oxide (iNO)
Trial: 23037875
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) alone
Trial: 20335831
Drug: Everolimus 0.75
RxNorm normalized name: everolimus 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 0.75 mg BID
Trial: 20335831
Drug: Everolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.5 mg BID
Trial: 17621415
Drug: Sulindac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (200 mg/day, 100 mg twice a day; n = 16 patients)
Trial: 9440402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preliminary notification, short questionnaire, and no mention of telephone contact
Trial: 9440402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of no preliminary notification, long questionnaire, and mention of telephone contact
Trial: 10781270
Drug: Hypnotic state
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic state
Trial: 26079661
Drug: Enhanced oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced oral healthcare
Trial: 26079661
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral healthcare
Trial: 27359067
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (4000 IU daily) for 2 months prior to surgery
Trial: 23895860
Drug: Dexmedetomidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.3 µg/kg loading dose, 0.3 µg·kg(‐1)·h(‐1) maintenance dose)
Trial: 22180397
Drug: Dose-dense weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-dense weekly paclitaxel 80 mg/m(2) plus 3-weekly carboplatin AUC 6
Trial: 22180397
Drug: 3-weekly paclitaxel/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly paclitaxel/carboplatin
Trial: 17116705
Drug: Chili (4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chili (4.2 g dry powder, 25 mg polyphenols as gallic acid equivalents)
Trial: 17116705
Drug: Turmeric (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (0.5 g dry powder, 50 mg polyphenols as gallic acid equivalents)
Trial: 17116705
Drug: Chili (4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chili (4.2 g dry powder)
Trial: 14742340
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% solution (0.7 ml x kg(‐1))
Trial: 14742340
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% solution (0.7 ml x kg(‐1))
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (40 mg and higher)
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (80 mg)
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (120 mg and 160 mg)
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (100 mg-140 mg)
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (100 mg upwards)
Trial: 10188789
Drug: WAL 2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WAL 2014 (40, 60, 80, 100, and 140 mg)
Trial: 653534
Drug: Pyridoxine administration
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine administration in normal postpartum women
Trial: 653534
Drug: Pyridoxine administration
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine administration in patients with chlorpromazine-induced hyperprolactinaemia
Trial: 26159452
Drug: Tweeting arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tweeting arm (intervention group) - three tweets daily using Hootsuite with specific content related to the systematic reviews.
Trial: 22001341
Drug: Vibration-assisted anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration-assisted anesthesia during BTX‐A injections
Trial: 22001341
Drug: BTX‐A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A injections alone (control)
Trial: 19441605
Drug: loratadine-montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine-montelukast (10 mg/10 mg)
Trial: 19441605
Drug: phenylephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylephrine (10 mg)
Trial: 8993254
Drug: Methylprednisolone 20
RxNorm normalized name: methylprednisolone 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 20 mg/kg body weight (S group)
Trial: 25375979
Drug: TNF‐α (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α (12 ng/kg/h) infusion
Trial: 22256576
Drug: FA plus
RxNorm normalized name: Medorfa Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA plus TH (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1 and Tramadol hydrochloride 2 mg kg‐1 . 24 hr‐1 after bolus injection of FA 50 mg)
Trial: 22256576
Drug: FA alone
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FA alone (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1)
Trial: 19565736
Drug: Pricking blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking blood therapy combined with ultraviolet irradiation
Trial: 19565736
Drug: Aciclovir and
RxNorm normalized name: Aciclovir and hydrocortisone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir and other western medicine
Trial: 15830732
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal treatment approaches
Trial: 7943451
Drug: mCPP (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCPP (0.1 mg/kg)
Trial: 8513291
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (200 mg starting dose, followed by 100 mg weekly)
Trial: 7118065
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg p.o.)
Trial: 2878867
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (5 mg sublingually)
Trial: 30053278
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg 25(OH)D3 daily
Trial: 30053278
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg vitamin D3 daily
Trial: 25093275
Drug: 135 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 g serving of lean beef (tinned meat) providing 20 g of protein and 1.7 g of fat after resistance training.
Trial: 21111314
Drug: Ultraviolet-A/riboflavin CXL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet-A/riboflavin CXL therapy
Trial: 18515652
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) for 3 months
Trial: 15837100
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of T. arjuna
Trial: 24766973
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily (15 mg if creatinine clearance is 30‐49 mL/min)
Trial: 24766973
Drug: Dose-adjusted vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted vitamin K antagonists (VKAs; INR 2.0‐3.0)
Trial: 24766973
Drug: Rivaroxaban or
RxNorm normalized name: rivaroxaban Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban or VKA administered for 21 to 56 days before cardioversion
Trial: 24766973
Drug: Rivaroxaban or
RxNorm normalized name: rivaroxaban Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban or VKA administered for 6 weeks postcardioversion
Trial: 1312002
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg
Trial: 11583728
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg, twice daily)
Trial: 11583728
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg, twice daily)
Trial: 10741176
Drug: 0.02% mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% mitomycin C solution
Trial: 2807523
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10^8 organisms)
Trial: 131976
Drug: Hydrocortisone hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone hemisuccinate (steroid group)
Trial: 131976
Drug: Non-steroid treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid treatment (control group)
Trial: 23336549
Drug: Problem-solving intervention
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving intervention (five weekly 90-minute group sessions)
Trial: 21700924
Drug: Hand‐arm intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand‐arm intensive bimanual therapy (HABIT)
Trial: 16625986
Drug: Sublingual desmopressin
RxNorm normalized name: desmopressin Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual desmopressin 160 microg
Trial: 16625986
Drug: Sublingual desmopressin
RxNorm normalized name: desmopressin Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual desmopressin 240 microg
Trial: 16625986
Drug: Sublingual desmopressin
RxNorm normalized name: desmopressin Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual desmopressin 320 microg
Trial: 16625986
Drug: Sublingual desmopressin
RxNorm normalized name: desmopressin Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual desmopressin (all doses)
Trial: 9154395
Drug: 1% Lamisil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Lamisil emulsion gel
Trial: 7895384
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium cromoglycate (single dose)
Trial: 7895384
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium cromoglycate (3-week course)
Trial: 3266156
Drug: Spironolactone (100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100‐200 mg/day)
Trial: 3266156
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (50‐100 mg/day)
Trial: 28708863
Drug: IL-2 administration
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 administration with therapeutic vaccination (ALVACHIV/Lipo-6T)
Trial: 22555974
Drug: IL-2 administration
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 administration
Trial: 23922114
Drug: Panobinostat 40
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 40 mg thrice weekly (initially), then reduced to 20 mg thrice weekly after nine patients due to safety concerns.
Trial: 12796155
Drug: Salmeterol, 50
RxNorm normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 50 micro g bid
Trial: 11007224
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of doses every 3 min until predefined levels of somnolence were achieved
Trial: 8985524
Drug: Mefloquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (25 mg/kg total, divided into 15 mg/kg initially and 10 mg/kg after 12 hours)
Trial: 1476911
Drug: Nifedipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (calcium blocker)
Trial: 29187594
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma urate (100 µmol/L increase)
Trial: 29187594
Drug: Genetically determined
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically determined high plasma urate (100 µmol/L increase)
Trial: 26891879
Drug: Novel glutamate-modulating
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Novel glutamate-modulating agents
Trial: 22527829
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (total dose 2160 mg i.v.) + 0.45% saline (1 mL/kg/h over 24 h)
Trial: 22527829
Drug: N-acetylcysteine (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (total dose 4800 mg p.o.) + 0.45% saline (1 mL/kg/h over 24 h)
Trial: 20484838
Drug: Beverages with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverages with apple polyphenols (600 mg)
Trial: 12097660
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (100 mg Fe/d as ferrous sulfate) for 6 weeks
Trial: 12097660
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (22 mg Zn/d as zinc gluconate) for 6 weeks
Trial: 10081531
Drug: Ketorolac 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.9 mg kg‐1 i.v.
Trial: 10081531
Drug: Pethidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.5 mg kg‐1 i.v.
Trial: 7593724
Drug: Moclobemide once
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide once daily (OD)
Trial: 7593724
Drug: Moclobemide three
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide three times daily (TDS)
Trial: 2407336
Drug: IF radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF radiotherapy + MOPP chemotherapy
Trial: 2407336
Drug: IF radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF radiotherapy + MOPP chemotherapy (CCSG and CALGB)
Trial: 30369321
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for OSA diagnosis and treatment
Trial: 30369321
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care for OSA diagnosis and treatment
Trial: 24909563
Drug: Conservative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatments (1 or more)
Trial: 19461562
Drug: 12.5 mg/mL
RxNorm normalized name: cresol 12.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/mL morphine with 0.2% ropivacaine
Trial: 19461562
Drug: 25 mg/mL
RxNorm normalized name: hemin 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/mL morphine with 0.2% ropivacaine
Trial: 17617283
Drug: Moxonidine 0.2
RxNorm normalized name: moxonidine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2 mg once daily (M0.2)
Trial: 17617283
Drug: Moxonidine 0.2
RxNorm normalized name: moxonidine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2 mg BID (M0.4)
Trial: 17617283
Drug: Moxonidine 0.2
RxNorm normalized name: moxonidine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2 mg plus Irbesartan 150 mg (M0.2+1)
Trial: 15165654
Drug: Skills training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skills training intervention (manual plus five weekly group-based sessions)